¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ÷°¡Á¦ ½ÃÀå µ¿Çâ, ½ÃÀå Á¡À¯À², ½ÃÀå ±Ô¸ð ¿¹Ãø(2021-2028³â) : Á¦Ç°(Æú¸®¿Ã, °¡¿ëÈÁ¦, °è¸é Ȱ¼ºÁ¦/À¯ÈÁ¦ ź¼öȹ°), Áö¿ªº°
Biopharmaceutical Excipients Market Size, Share & Trends Analysis Report By Product (Polyols, Solubilizers & Surfactants/Emulsifiers, Carbohydrates), By Region, And Segment Forecasts, 2021 - 2028
¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ÷°¡Á¦ ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 6.5%ÀÇ CAGR·Î 2028³â 34¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß Áõ°¡, ¾à¹° ¹× ¹é½Å ºÒ¾ÈÁ¤, ½Å¾à °³¹ß¿¡ ´ëÇÑ ÃÊÁ¡ È®´ë µîÀÇ ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ÷°¡Á¦(Biopharmaceutical Excipients) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç ½ÃÀå Á¤ÀÇ ¹× °³¿ä, Äڷγª19(COVID-19) ¹× ±âŸ ½ÃÀå ¿µÇâ ¿äÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ¡¤¿¹Ãø, Á¦Ç°¡¤Áö¿ª/ÁÖ¿ä±¹ µî °¢Á¾ ±¸ºÐº° ºÐ¼®, °æÀï ȯ°æ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
Á¦1Àå °³¿ä
Á¦2Àå Á¶»ç ¹æ¹ý¡¤Á¶»ç ¹üÀ§
Á¦3Àå ½ÃÀå º¯¼ö¡¤µ¿Ç⡤Àü¸Á
- ½ÃÀå ±¸ºÐ¡¤¹üÀ§
- º¸±Þ ¹× ¼ºÀå Àü¸Á ¸ÅÇÎ
- SWOT ºÐ¼®
- Æ÷ÅÍÀÇ 5¼¼·Â ¸ðÇü
- COVID-19 : ¿µÇ⠺м®
Á¦4Àå ½ÃÀå ¿¹Ãø¡¤µ¿Ç⠺м® : Á¦Ç°º°
- °¡¿ëÈÁ¦, °è¸é Ȱ¼ºÁ¦/À¯ÈÁ¦
- Æ®¸®±Û¸®¼¼¸®µå
- ¿¡½ºÅ׸£
- ±âŸ
- Æú¸®¿Ã
- ź¼öȹ°
- µ¦½ºÆ®·Î¿À½º
- ÀÚ´ç
- ÀüºÐ
- ±âŸ
- Àü¿ë ºÎÇüÁ¦
Á¦5Àå ½ÃÀå ¿¹Ãø¡¤µ¿Ç⠺м® : Áö¿ª ¹× ÁÖ¿ä ±¹°¡º°
- ½ÃÀå Á¡À¯À² ½ÇÀû¡¤¿¹Ãø
- ½ÃÀå ±Ô¸ð ÃßÀÌ¡¤¿¹Ãø
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦6Àå °æÀï »óȲ
- Àü·« ÇÁ·¹ÀÓ¿öÅ©
- Âü°¡ »ç¾÷ÀÚ ºÐ·ù
- ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Merck KGaA
- Signet Chemical Corporation Pvt. Ltd.
- Sigachi Industries Pvt. Ltd.
- Associated British Foods
- Spectrum Chemical Manufacturing Corp.
- Roquette Freres
- IMCD
- Clariant
- DFE Pharma
- Colorcon
- J. RETTENMAIER&SOHNE GmbH Co KG
- BASF SE
- Evonik Industries AG
NJH 21.03.19
Biopharmaceutical Excipients Market Growth & Trends
The global biopharmaceutical excipients market size is expected to reach USD 3.4 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.5% from 2021 to 2028. The factors driving the market growth include increasing development of biosimilars, instability associated with drugs & vaccines, and growing focus on the development of novel drugs, among others.
The changing regulatory scenarios by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have impacted drug development. Several legislative proposals are addressing new ways for lowering the cost of prescription drugs. Similarly, in recent years there is an increasing focus on drug-manufacturing quality has led to several recalls by FDA and the EMA. Hence, the stringent investigations related to an examination of drugs are likely to promote the use of specific excipients for developing efficient drugs.
In addition, companies are collaborating with government authorities for increasing the application of novel compounds. For instance, in December 2019, U.S. FDA started a pilot program to evaluate novel biopharmaceutical excipients. Later, the initiative was supported by several companies such as AstraZeneca, Regeneron, and Janssen for FDA's plan to review novel biopharmaceutical excipients. Regeneron highlighted different novel compounds that can potentially help in improving public health for example hydrophobic salts can reduce the viscosity of highly concentrated antibody formulations.
Moreover, the rising focus on the rapid development of COVID-19 vaccines and therapeutic drugs is further driving the market growth. Excipients have an essential role in the development of biologics as it helps in stabilizing the drug during storage and processing. The use of appropriate biopharmaceutical excipients enables the development of novel therapies and robust pharmaceutical products for fighting against the pandemic.
Large-scale pharmaceutical companies signed a long-term supply agreement with companies for supporting the development of COVID-19 vaccines. For instance, in November 2020, Pfizer Inc. signed a five-year contract with Croda International for lipid-based excipients that will be used for manufacturing Pfizer's COVID-19 vaccine candidate. Similarly, in May 2020, Moderna signed a supply agreement with CordenPharma for the large-scale production of lipid excipient for the development of mRNA-1273, Moderna's COVID-19 vaccine candidate.
Biopharmaceutical Excipients Market Report Highlights
Carbohydrates accounted for the largest revenue share of 36.2% in 2020 owing to the increasing use of carbohydrates owing to their several advantages
The advantages include it helps the efficient binding of tablet ingredients, enables accurate dosing and protecting the tablet from harsh environmental conditions, among others
Sucrose amongst the carbohydrates dominated with a market share of 32.8% owing to its increasing application in stabilizing proteins
Starch is expected to witness the fastest CAGR of 6.6% from 2021 to 2028 owing to the increasing launch of new starch excipients
For instance, in May 2019, Colorcon Inc. launched STARTAB, a new starch tableting excipient. It is developed by directly compressible starch for enhancing the stability of moisture sensitive API
North America has emerged as the highest revenue-generating region, representing a market share of 32.0% in 2020
Large pharmaceutical companies are entering in collaboration with the companies in the region which can be attributed to market growth
For instance, in February 2020, MilliporeSigma entered in an agreement with ReForm Biologics LLC for commercializing ReForm's excipients that are used in biotherapeutic formulations
In Asia Pacific, the market is expected to witness a lucrative CAGR of 7.0% from 2021 to 2028 owing to the increasing production of biosimilar drugs in the region
The government in this region is promoting biosimilar development. For instance, the government of South Korea provided regulatory guidance to local biosimilars companies for aiming to develop around 22.0% of global biosimilars by 2020
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Methodology and Scope
- 2.1 Market Segmentation & Scope
- 2.1.1Estimates and Forecast Timeline
- 2.2 Research Methodology
- 2.3 Information Procurement
- 2.3.1 Purchased database:
- 2.3.2 GVR's internal database
- 2.3.3 Secondary sources:
- 2.3.4 Primary Research:
- 2.3.5 Details of Primary Research
- 2.3.5.1 Data for primary interviews in North America
- 2.3.5.2 Data for primary interviews in Europe
- 2.3.5.3 Data for primary interviews in Asia Pacific
- 2.3.5.4 Data for primary interviews in Latin America
- 2.3.5.5 Data for primary interviews in Middle East & Africa
- 2.4 Information or Data Analysis
- 2.4.1Data Analysis Models
- 2.5 Market Formulation & Validation
- 2.6 Model Details
- 2.6.1Commodity Flow Analysis (Model 1)
- 2.6.1.1 Approach 1: Commodity Flow Approach
- 2.6.2Volume Price Analysis (Model 2)
- 2.6.2.1 Approach 2: Volume Price Analysis
- 2.7 List of Secondary Sources
- 2.8 List of Primary Sources
- 2.9 Objectives
- 2.9.1 Objective 1:
- 2.9.2 Objective 2:
Chapter 3 Market Variables, Trends & Scope
- 3.1 Market Segmentation & Scope
- 3.1.1 Market driver analysis
- 3.1.1.1 Chemical and physical instability of biopharmaceuticals is boosting the development of excipients
- 3.1.1.2 Increase in focus of pharmaceutical players on bio generic market
- 3.1.1.3 Cost-efficiency and competency of manufacturers
- 3.1.1.4 Patent expiry of biological actives
- 3.1.1.5 Rising adoption of multifunctional excipients
- 3.1.2 Market restraint analysis
- 3.1.2.1 Challenges in development of excipients for biologics
- 3.1.2.2 Issues pertaining to supply chain in biopharmaceutical industry
- 3.2 Penetration & Growth Prospect Mapping for Products, 2020
- 3.3 Biopharma Excipients Market-SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
- 3.4 Industry Analysis - Porter's
- 3.5 Biopharmaceutical Excipients Market: COVID-19 Impact Analysis
Chapter 4 Market Categorization: Product Estimates & Trend Analysis
- 4.1 Biopharmaceutical Excipients Market: Product Movement Analysis, 2020 & 2028
- 4.2 Solubilizers & Surfactants/Emulsifiers
- 4.2.1 Global solubilizers & surfactants/emulsifiers market, by revenue 2017 - 2028(USD Million)
- 4.2.2 Global solubilizers & surfactants/emulsifiers market, by volume 2017 - 2028 (Tonnes)
- 4.2.3 Triglycerides
- 4.2.3.1 Global triglycerides market, by revenue 2017 - 2028 (USD Million)
- 4.2.3.2 Global triglycerides market, by volume 2017 - 2028 (Tonnes)
- 4.2.4 Esters
- 4.2.4.1 Global esters market, by revenue 2017 - 2028 (USD Million)
- 4.2.4.2 Global esters market, by volume by 2017 - 2028 (Tonnes)
- 4.2.5 Other solubilizers
- 4.2.5.1 Global other solubilizers market, by revenue 2017 - 2028 (USD Million)
- 4.2.5.2 Global other solubilizers market, by volume 2017 - 2028 (Tonnes)
- 4.3 Polyols
- 4.3.1 Global polyols market, by revenue 2017 - 2028 (USD Million)
- 4.3.2 Global polyols market, by volume 2017 - 2028 (Tonnes)
- 4.3.3 Mannitol
- 4.3.3.1 Global mannitol market, by revenue 2017 - 2028 (USD Million)
- 4.3.3.2 Global mannitol market, by volume 2017 - 2028 (Tonnes)
- 4.3.4 Sorbitol
- 4.3.4.1 Global sorbitol market, by revenue 2017 - 2028 (USD Million)
- 4.3.4.2 Global sorbitol market, by volume 2017 - 2028 (Tonnes)
- 4.3.5 Other polyols
- 4.3.5.1 Global other polyols market, by revenue 2017 - 2028 (USD Million)
- 4.3.5.2 Global other polyols market, by volume 2017 - 2028 (Tonnes)
- 4.4 Carbohydrates
- 4.4.1 Global carbohydrates market, by revenue 2017 - 2028 (USD Million)
- 4.4.2 Global carbohydrates market, by volume 2017 - 2028 (Tonnes)
- 4.4.3 Dextrose
- 4.4.3.1 Global dextrose market, by revenue 2017 - 2028 (USD Million)
- 4.4.3.2 Global dextrose market, by volume 2017 - 2028 (Tonnes)
- 4.4.4 Sucrose
- 4.4.4.1 Global sucrose market, by revenue 2017 - 2028 (USD Million)
- 4.4.4.2 Global sucrose market, by volume 2017 - 2028 (Tonnes)
- 4.4.5 Starch
- 4.4.5.1 Global starch market, by revenue 2017 - 2028 (USD Million)
- 4.4.5.2 Global starch market, by volume 2017 - 2028 (Tonnes)
- 4.4.6 Other carbohydrate excipients
- 4.4.6.1 Global other carbohydrates market, by revenue 2017 - 2028 (USD Million)
- 4.4.6.2 Global other carbohydrates market, by volume 2017 - 2028 (Tonnes)
- 4.5 Specialty Excipients
- 4.5.1 Global specialty excipients/others market, by revenue 2017 - 2028 (USD Million)
- 4.5.2 Global specialty excipients/others market, by volume 2017 - 2028 (Tonnes)
Chapter 5 Market Categorization: Regional Estimates & Trend Analysis, by Product
- 5.1 Biopharmaceutical Excipients Market Share By Region, 2020 & 2028
- 5.2 North America
- 5.2.1 North America biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.2.2 U.S.
- 5.2.2.1U.S. biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.2.3 Canada
- 5.2.3.1 Canada biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.3 Europe
- 5.3.1 Europe biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.3.2 Germany
- 5.3.2.1 Germany biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.3.3 U.K.
- 5.3.3.1 U.K. biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.2 Japan
- 5.4.2.1 Japan biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.3 China
- 5.4.3.1 China biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.4 India
- 5.4.4.1 India biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.5 Malaysia
- 5.4.5.1 Malaysia biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.6 South Korea
- 5.4.6.1 South Korea biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.7 Philippines
- 5.4.7.1 Philippines biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.8 New Zealand
- 5.4.8.1 New Zealand biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.9 Australia
- 5.4.9.1 Australia biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.10 Singapore
- 5.4.10.1 Singapore biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.4.11 Indonesia
- 5.4.11.1 Indonesia biopharma excipients market, by revenue 2017 - 2028 (USD Million)
- 5.5 Latin America
- 5.5.1 Latin America biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.5.2 Brazil
- 5.5.2.1 Brazil biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.6 Middle East & Africa (MEA)
- 5.6.1 Middle East & Africa biopharmaceutical excipients market, 2017 - 2028 (USD Million)
- 5.6.2 South Africa
- 5.6.2.1 South Africa biopharmaceutical excipients market, 2017 - 2028 (USD Million)
Chapter 6 Competitive Landscape
- 6.1 Strategy Framework
- 6.2 Market Participation Categorization
- 6.3 Company Profiles
- 6.3.1 Merck KGaA
- 6.3.1.1 Company overview
- 6.3.1.1.1 Merck Millipore
- 6.3.1.2 Financial performance
- 6.3.1.3 Product benchmarking
- 6.3.1.4 Strategic initiatives
- 6.3.2 Signet Chemical Corporation Pvt. Ltd.
- 6.3.2.1 Company overview
- 6.3.2.2 Financial performance
- 6.3.2.3 Product benchmarking
- 6.3.2.4 Strategic initiatives
- 6.3.3 Sigachi Industries Pvt. Ltd.
- 6.3.3.1 Company overview
- 6.3.3.2 Financial performance
- 6.3.3.3 Product benchmarking
- 6.3.3.4 Strategic initiatives
- 6.3.4 Associated British Foods
- 6.3.4.1 Company overview
- 6.3.4.2 ABITEC
- 6.3.4.2.1 Company overview
- 6.3.4.3 SPI Pharma
- 6.3.4.3.1 Company overview
- 6.3.4.4 Financial performance
- 6.3.4.4.1 Financial performance: ABITEC
- 6.3.4.4.1 Financial performance: SPI Pharma, Inc
- 6.3.4.5 Product benchmarking
- 6.3.4.6 Strategic initiatives
- 6.3.5 Spectrum Chemical Manufacturing Corp.
- 6.3.5.1 Company overview
- 6.3.5.2 Financial performance
- 6.3.5.3 Product benchmarking
- 6.3.5.4 Strategic initiatives
- 6.3.6 Roquette Freres
- 6.3.6.1 Company overview
- 6.3.6.2 Financial performance
- 6.3.6.3 Product benchmarking
- 6.3.6.4 Strategic initiatives
- 6.3.7 IMCD
- 6.3.7.1 Company overview
- 6.3.7.1.1 Indchem International
- 6.3.7.2 Financial performance
- 6.3.7.3 Product benchmarking
- 6.3.7.4 Strategic initiatives
- 6.3.8 Clariant
- 6.3.8.1 Company overview
- 6.3.8.2 Financial performance
- 6.3.8.3 Product benchmarking
- 6.3.8.4 Strategic initiatives
- 6.3.9 DFE Pharma
- 6.3.9.1 Company overview
- 6.3.9.2 Product benchmarking
- 6.3.9.3 Strategic initiatives
- 6.3.10 Colorcon
- 6.3.10.1 Company overview
- 6.3.10.2 Financial performance
- 6.3.10.3 Product benchmarking
- 6.3.10.4 Strategic initiatives
- 6.3.11 J. RETTENMAIER & SOHNE GmbH + Co KG
- 6.3.11.1 Company overview
- 6.3.11.2 JRS PHARMA
- 6.3.11.3 Company overview
- 6.3.11.4 Financial performance
- 6.3.11.5 Product benchmarking
- 6.3.11.6 Strategic initiatives
- 6.3.12 BASF SE
- 6.3.12.1 Company overview
- 6.3.12.2 Financial performance
- 6.3.12.3 Product benchmarking
- 6.3.12.4 Strategic initiatives
- 6.3.13 Evonik Industries AG
- 6.3.13.1 Company overview
- 6.3.13.2 Financial performance
- 6.3.13.3 Product benchmarking
- 6.3.13.4 Strategic initiatives